State Key Laboratory of Oncology in Southern China, Department of Radiation Oncology, Cancer Center, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):661-8. doi: 10.1016/j.ijrobp.2010.03.024. Epub 2010 Jul 17.
To compare the results of intensity-modulated radiotherapy (IMRT) with those of two-dimensional conventional radiotherapy (2D-CRT) in the treatment of patients with nasopharyngeal carcinoma (NPC).
A retrospective review of data from 1,276 patients with biopsy-proven, nonmetastatic NPC was performed. All patients had undergone magnetic resonance imaging and were staged according to the sixth edition of the American Joint Committee on Cancer staging criteria. Radiotherapy was the primary treatment for all patients.
Of the 1,276 patients, 512 were treated with IMRT and 764 with 2D-CRT. The 5-year actuarial local relapse-free survival (LRFS), the nodal relapse-free survival (NRFS), the distant metastasis-free survival (DMFS), and the disease-free survival (DFS) rates were 92.7%, 97.0%, 84.0%, and 75.9%, respectively, for the IMRT group, and 86.8%, 95.5%, 82.6%, and 71.4%, respectively, for the 2D-CRT group. In stage T1 patients, improvement of LRFS in the IMRT group was even significantly higher than in the 2D-CRT group (100% vs. 94.4%; p = 0.016). A trend of improvement of DFS was observed in the IMRT group compared with the 2D-CRT group but without reaching statistical significance. NRFS and DMFS rates were similar in the two groups.
A greater improvement of treatment results with IMRT than with 2D-CRT was demonstrated primarily by achieving a higher local tumor control rate in NPC patients, especially in the early T stage patients. The goal of better control of both local failure in advanced, nonmetastatic NPC patients and of distant failure should be addressed in future studies.
比较调强放疗(IMRT)与二维常规放疗(2D-CRT)治疗鼻咽癌(NPC)患者的结果。
对 1276 例经活检证实、无远处转移的 NPC 患者的资料进行回顾性分析。所有患者均行磁共振成像检查,并根据美国癌症联合委员会第 6 版分期标准进行分期。所有患者均行放疗。
1276 例患者中,512 例行 IMRT,764 例行 2D-CRT。IMRT 组的 5 年局部无复发生存率(LRFS)、无区域淋巴结复发生存率(NRFS)、无远处转移生存率(DMFS)和无病生存率(DFS)分别为 92.7%、97.0%、84.0%和 75.9%,2D-CRT 组分别为 86.8%、95.5%、82.6%和 71.4%。在 T1 期患者中,IMRT 组的 LRFS 改善甚至显著高于 2D-CRT 组(100% vs. 94.4%;p = 0.016)。与 2D-CRT 组相比,IMRT 组的 DFS 有改善趋势,但无统计学意义。两组的 NRFS 和 DMFS 率相似。
与 2D-CRT 相比,IMRT 治疗 NPC 患者的结果有较大改善,主要表现为局部肿瘤控制率更高,尤其是早期 T 分期患者。未来的研究应关注如何更好地控制晚期、无远处转移 NPC 患者的局部失败和远处失败。